1. ALLA AKTIER
  2. NYHETER
  3. ONCOZENGE

OncoZenge

Nyheter OncoZenge Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

OncoZenge AB Publishes Annual Report for 2025

MARKN.

OncoZenge AB (publ) ("OncoZenge" or "the Company") hereby publishes the annual report for 2025.

The 2025 annual report is available as an attached document and in the PDF format on the company’s website at https://oncozenge.se/investors/.

BupiZenge™ - Potential to be the leading treatment for oral pain.

Contacts
Stian Kildal CEO Mobile: +46 76 115 3797 E-mail: stian.kildal@oncozenge.se
Michael Owens CFO Mobile: +46 73 324 4988 E-mail: michael.owens@oncozenge.se

About
OncoZenge AB (publ) is a clinical-stage pharmaceutical company developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options are insufficient, such as oral mucositis from cancer therapy. Its lead candidate, BupiZenge™, represents a novel formulation of bupivacaine in a lozenge form, aimed at providing rapid and sustained local pain relief without the risks associated with systemic opioids. OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ. For more information, please visit www.oncozenge.se.

OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden

Certified Adviser
Redeye Nordic Growth AB is the company’s Certified Adviser.

Attachments
Annual Report 2025 2026 04 29 16 29 57

Datum 2026-04-30, kl 08:00
Källa MFN
Bifogade filer
Annual Report 2025 2026 04 29 16 29 57